Sumitomo Pharma Co Ltd banner

Sumitomo Pharma Co Ltd
OTC:SMDPY

Watchlist Manager
Sumitomo Pharma Co Ltd Logo
Sumitomo Pharma Co Ltd
OTC:SMDPY
Watchlist
Price: 9.05 USD Market Closed
Market Cap: $3.6B

Wall St Price Targets

SMDPY Price Targets Summary
Sumitomo Pharma Co Ltd

Wall Street analysts forecast SMDPY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SMDPY is 12.85 USD with a low forecast of 9.16 USD and a high forecast of 17.14 USD.

Lowest Forecast
Price Target
9.16 USD
1% Upside
Average Forecast
Price Target
12.85 USD
42% Upside
Highest Forecast
Price Target
17.14 USD
89% Upside
Sumitomo Pharma Co Ltd Competitors:
Price Targets
INMB
INmune Bio Inc
458% Upside

Revenue
Forecast

1% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
1% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 3 years is 11%.

Gross Profit
Forecast

0% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
0% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 0%. The projected CAGR for the next 3 years is 13%.

Operating Income
Forecast

-1% / Year
Past Growth
-26% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
-1% / Year
Past Growth
-26% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been -1%. The projected CAGR for the next 2 years is -26%.

Pre-Tax Income
Forecast

1% / Year
Past Growth
84% / Year
Estimated Growth
Estimates Accuracy
9%
Average Beat
1% / Year
Past Growth
84% / Year
Estimated Growth
Estimates Accuracy
9%
Average Beat

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 1%. The projected CAGR for the next 3 years is 84%.

Net Income
Forecast

8% / Year
Past Growth
48% / Year
Estimated Growth
Estimates Accuracy
14%
Average Beat
8% / Year
Past Growth
48% / Year
Estimated Growth
Estimates Accuracy
14%
Average Beat

Over the last 13 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 3 years is 48%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SMDPY's stock price target?
Price Target
12.85 USD

According to Wall Street analysts, the average 1-year price target for SMDPY is 12.85 USD with a low forecast of 9.16 USD and a high forecast of 17.14 USD.

What is the Revenue forecast for Sumitomo Pharma Co Ltd?
Projected CAGR
11%

Over the last 13 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 3 years is 11%.

What is the Gross Profit forecast for Sumitomo Pharma Co Ltd?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 0%. The projected CAGR for the next 3 years is 13%.

What is the Operating Income forecast for Sumitomo Pharma Co Ltd?
Projected CAGR
-26%

Over the last 13 years, the compound annual growth rate for Operating Income has been -1%. The projected CAGR for the next 2 years is -26%.

What is the Pre-Tax Income forecast for Sumitomo Pharma Co Ltd?
Projected CAGR
84%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 1%. The projected CAGR for the next 3 years is 84%.

What is the Net Income forecast for Sumitomo Pharma Co Ltd?
Projected CAGR
48%

Over the last 13 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 3 years is 48%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett